



Canada is using the same formulation as many other countries, allowing for greater flexibility in supply of product and continuous treatment support for patients.

**BACK
IN STOCK
100 TABLET
BOTTLE**



WHAT HAS CHANGED?

NOW
Lactose
Free

Revised
Tablet
Indication

Updated
Product
Monograph

Now only for the relief of
smooth muscle spasm/cramping
of the GI system

[CLICK HERE](#)



TARGETED RELIEF

For abdominal pain and discomfort. Works at the site of pain, where the cramps occur – in the GI system




WELL-TOLERATED

With a proven safety profile. Very little is absorbed into the bloodstream (low bioavailability)



GENTLE ON THE STOMACH*

Hyoscine butylbromide is derived from a natural source: the Duboisia plant



DUAL-BENEFIT

Relaxes the cramps and relieves the pain

* Buscopan® side effects, as a substance that blocks the neurotransmitter acetylcholine, are generally mild and limited.



**65+
YEARS**
ON THE MARKET²

CURRENTLY AVAILABLE IN
**90+
COUNTRIES**²

#1
**RECOMMENDED
BRAND**WORLDWIDE
IN ABDOMINAL CRAMPING RELIEF²

DOSAGE¹

One or two 10 mg tablets per day up to a **maximum of 6** tablets per day. In prolonged illness which requires repeated dosing, 1 tablet 3 to 5 times a day is recommended. In case a dose has been missed, take the next dose as scheduled. Do not double the dose.

COMPOSITION¹

Medicinal ingredient: hyoscine butylbromide.

Non-medicinal ingredients: acacia, anhydrous dibasic calcium phosphate, carnauba wax, colloidal silicon dioxide, corn starch, modified starch, polyethylene glycol 6000, povidone, stearic acid, sucrose, talc, tartaric acid, titanium dioxide, and white wax.

For more information:

Please consult the Product Monograph at <http://products.sanofi.ca/en/buscopan.pdf> or contact the sponsor, Sanofi-Aventis Canada Inc., at 1-800-265-7927 for important information to assist in benefit-risk assessment. Always direct the patient to read and follow the label.

REFERENCES

1. Sanofi-Aventis Canada Inc. **Buscopan**® Product Monograph. September 6, 2018.
2. Sanofi-Aventis Canada Inc. **Buscopan**® Data on File. 2017.



SACA.BUSC.19.03.0206a